Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Biden-era ...

The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Medicare drug ...

Trump’s “big beautiful” bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of ...

Relief is coming for more than 5 million Medicare beneficiaries who rely on expensive prescription medications.

Bruce Leuchter, CEO, Neurvati, explains why aligning drug development with patient-reported outcomes is key to demonstrating value and achieving payer alignment in the rare disease space.